TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34452927

Group type: EXPERIMENTAL
Intervention: rhIL-7 (CYT107)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 54
Study: 32739704

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) 3x/week for 6 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Basic stretching activities (control) 3x/week for 6 weeks
Number of subjects: 42
Study: 36352294

Group type: EXPERIMENTAL
Intervention: PATHS intervention
Number of subjects: 61
Study: 33590823

Group type: EXPERIMENTAL
Intervention: Lemborexant (5 mg and 10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zolpidem
Number of subjects: 0
Study: 36041668

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study: 34454953

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) treatment
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 220
Study: 35439033

Group type: EXPERIMENTAL
Intervention: Chinese Herbal Medicine (SXC) - 3 capsules (0.5 g/capsule) taken 3 times a day for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 0
Study: 35051939

Group type: EXPERIMENTAL
Intervention: GCMO (internet-based self-help intervention)
Number of subjects: 351

Group type: COMPARATOR
Intervention: MHA-W (mental health advice waiting group)
Number of subjects: 351
Study: 33037801

Group type: EXPERIMENTAL
Intervention: Etodolac (300 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ibuprofen (600 mg)
Number of subjects: 30
Study: 33125454

Group type: EXPERIMENTAL
Intervention: CERC‐501 (10 mg/d for 6 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CERC‐501 (20 mg/d for 6 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CERC‐501 (10 mg/d for 3 days after placebo for 3 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CERC‐501 (20 mg/d for 3 days after placebo for 3 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (6 days)
Number of subjects: 8
Study: 35420362

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 34622768

Group type: EXPERIMENTAL
Intervention: Menopur liquid (450 IU, 600 IU/0.96 mL)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Menopur powder (450 IU, by 2 subcutaneous injections of 225 IU in 1 mL)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 76
Study: 32776611

Group type: EXPERIMENTAL
Intervention: bretylium tosylate (10 mm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 20
Study: 35849181

Group type: EXPERIMENTAL
Intervention: Mindfulness-based supportive psychotherapy (SP) for 6 sessions of 90-min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study: 34358701

Group type: EXPERIMENTAL
Intervention: Tezepelumab (70 mg or 210 mg every 4 weeks or 280 mg every 2 weeks)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study: 33723662

Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Xenogeneic Dermal Matrix (XDM)
Number of subjects: 15
Study: 32005777

Group type: EXPERIMENTAL
Intervention: 18F‐DPA‐714 PET
Number of subjects: 37
Study: 34245243

Group type: EXPERIMENTAL
Intervention: ccIIV4
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: RIV4
Number of subjects: 727

Group type: COMPARATOR
Intervention: IIV4
Number of subjects: 727
Study: 32497489

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Tranexamic Acid (DT) group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dexmedetomidine (DS) group
Number of subjects: 36
Study: 35683351

Group type: EXPERIMENTAL
Intervention: Low-dose hzVSF-v13
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-dose hzVSF-v13
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 33206670

Group type: EXPERIMENTAL
Intervention: Small-sided recreational team handball training (THG) for 12 weeks, 1.8 times/week
Number of subjects: 54
Study: 36163874

Group type: EXPERIMENTAL
Intervention: Pirtobrutinib monotherapy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Bendamustine plus Rituximab (BR)
Number of subjects: 250
Study: 34579783

Group type: EXPERIMENTAL
Intervention: Personalised Self-management Support Programme (P-SUP) for 18 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (waiting control group)
Number of subjects: 0
Study: 32907828

Group type: EXPERIMENTAL
Intervention: Dual-hormone (DH) closed-loop control
Number of subjects: 23

Group type: COMPARATOR
Intervention: Insulin-only single-hormone (SH) closed-loop control
Number of subjects: 23

Group type: COMPARATOR
Intervention: Predictive low glucose suspend (PLGS) system
Number of subjects: 23
Study: 34632845

Group type: EXPERIMENTAL
Intervention: Protocolized, multimodal weaning strategy implemented by a multidisciplinary care team
Number of subjects: 0
Study: 34656197

Group type: EXPERIMENTAL
Intervention: Cognitive-only psychotherapy (n = 21)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Behavioral-only psychotherapy (n = 21)
Number of subjects: 42
Study: 32800913

Group type: EXPERIMENTAL
Intervention: K levels ≥4.5 mEq/L within 36-56 hours prior to AKI diagnosis
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: K levels in AKI group
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: K levels in STEMI patients
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: K levels in NSTEMI patients
Number of subjects: 430

Group type: COMPARATOR
Intervention: Control group (no AKI)
Number of subjects: 430
Study: 34931749

Group type: EXPERIMENTAL
Intervention: Berberine (600 mg/d)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 33206126

Group type: EXPERIMENTAL
Intervention: Tailored self-care intervention (home visit within 7 days of discharge and twice-monthly telephone coaching for 3 months)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Tailored self-care intervention
Number of subjects: 479

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 479
Study: 35598594

Group type: EXPERIMENTAL
Intervention: Fractionated 5-aminolevulinic acid 20% (ALA)-PDT
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional two-stage methyl aminolevulinate (MAL)-PDT
Number of subjects: 162

Group type: COMPARATOR
Intervention: MAL-PDT
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 162
Study: 34175716

Group type: EXPERIMENTAL
Intervention: Yoga exercise three times a week for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 64
Study: 32060531

Group type: EXPERIMENTAL
Intervention: Microbial phytase supplementation at 0, 750, 1,500, or 3,000 FTU/kg diet (Exp. 1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Microbial phytase supplementation at 0 or 1,500 FTU/kg diet (Exp. 2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No phytase supplementation (Control)
Number of subjects: 8

Group type: COMPARATOR
Intervention: RSC diet (Control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Microbial phytase supplementation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Phytase supplementation
Number of subjects: 8
Study: 34062004

Group type: EXPERIMENTAL
Intervention: Selinexor plus bortezomib-dexamethasone (XVd)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Bortezomib-dexamethasone (Vd)
Number of subjects: 402
Study: 33044213

Group type: EXPERIMENTAL
Intervention: Bright light treatment via ear canals
Number of subjects: 27
Study: 33290538

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 140

Group type: COMPARATOR
Intervention: Tofacitinib 10 mg BID
Number of subjects: 140
Study: 32393129

Group type: EXPERIMENTAL
Intervention: Copayment assistance voucher intervention
Number of subjects: 10102

Group type: COMPARATOR
Intervention: Usual care (no voucher)
Number of subjects: 10102
Study: 35514035

Group type: EXPERIMENTAL
Intervention: Soybean hulls low‐fibre (SHL, 6.00% crude fibre)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Soybean hulls high‐fibre (SHH, 8.00% crude fibre)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Corn stalk high‐fibre (CSH, 8.00% crude fibre)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Corn stalk low‐fibre (CSL, 6.00% crude fibre)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (CON, 3.15% crude fibre)
Number of subjects: 40
Study: 33270989

Group type: EXPERIMENTAL
Intervention: Preoperative C-reactive protein (pre-CRP) ≥3.1 mg/L (high-pre-CRP)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Postoperative maximum C-reactive protein (post-CRPmax) ≥77.1 mg/L (high-post-CRPmax)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (ACT)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Pre-CRP <3.1 mg/L
Number of subjects: 401
Study: 32446675

Group type: EXPERIMENTAL
Intervention: Mastery Learning
Number of subjects: 146

Group type: COMPARATOR
Intervention: See One, Do One
Number of subjects: 146
Study: 35811226

Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrates (POC) intake in Fpo and Spo groups
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (F and S groups without carbohydrates)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: All groups (including Fpo, Spo, F, and S)
Number of subjects: 200
Study: 33847366

Group type: EXPERIMENTAL
Intervention: Training in guideline-oriented biopsychosocial management of LBP (3-7 days training)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 234
Study: 35819352

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo ingestion
Number of subjects: 14
Study: 32575387

Group type: EXPERIMENTAL
Intervention: Whole almonds
Number of subjects: 105

Group type: COMPARATOR
Intervention: Isocaloric control snacks
Number of subjects: 105
Study: 36177001

Group type: EXPERIMENTAL
Intervention: High autophagy status and high immune status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autophagy-immune-related prognostic risk model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-risk group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-risk group
Number of subjects: 0
Study: 34475473

Group type: EXPERIMENTAL
Intervention: T3-T4 sympathicotomy
Number of subjects: 42

Group type: COMPARATOR
Intervention: T3-T4 gray ramicotomy
Number of subjects: 42
Study: 34780798

Group type: EXPERIMENTAL
Intervention: 180 μg/mL rhNGF eye drops, 3 times daily for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle control eye drops
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 180 μg/mL rhNGF eye drops
Number of subjects: 60
Study: 33930541

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in low-risk group
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in variable-risk group
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seroprevalence in high-risk group
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Overall SARS-CoV-2 seroprevalence
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Seropositivity in males
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Seropositivity in workers residing in high-prevalence areas
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Seropositivity in supporting services workers compared to doctors
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Seropositivity in administration staff compared to doctors
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Seropositivity in nurses compared to doctors
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Rate of previously undetected infection
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: High district prevalence as a factor for seropositivity in low-risk group
Number of subjects: 1078
Study: 36299404

Group type: EXPERIMENTAL
Intervention: Digital scan
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional impression
Number of subjects: 96
Study: 36462032

Group type: EXPERIMENTAL
Intervention: High-dose remimazolam (Group H, 0.08 mg/kg)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Medium-dose remimazolam (Group M, 0.06 mg/kg)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (Group C, 0.9% saline)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Low-dose remimazolam (Group L, 0.04 mg/kg)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (Group C) for elderly patients
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Medium-dose remimazolam (Group M)
Number of subjects: 204
Study: 33168945

Group type: EXPERIMENTAL
Intervention: Action-based cognitive remediation (ABCR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 45
Study: 34415830

Group type: EXPERIMENTAL
Intervention: mnemoPQQ® (PQQ disodium salt: 21.5 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 34349371

Group type: EXPERIMENTAL
Intervention: Facemask (Group M)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) (Group L)
Number of subjects: 89
Study: 35410931

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (one home visit, unsupervised exercise training, and motivational telephone calls)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Centre-based pulmonary rehabilitation (supervised exercise training for 8 weeks)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness evaluation
Number of subjects: 490
Study: 32460297

Group type: EXPERIMENTAL
Intervention: Warm application
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 34081062

Group type: EXPERIMENTAL
Intervention: Directional assistance to the closest AED
Number of subjects: 35

Group type: COMPARATOR
Intervention: No directional assistance
Number of subjects: 35
Study: 33453714

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corn oil (Control)
Number of subjects: 0
Study: 32713115

Group type: EXPERIMENTAL
Intervention: Plastic Stent (PS)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Uncovered Self-Expandable Metal Stent (uSEMS)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 53
Study: 34351562

Group type: EXPERIMENTAL
Intervention: Diet supplemented with nano or micro zinc oxide (49, 74, 99, and 124 mg ZnO/kg diet)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Diet supplemented with nano or micro zinc oxide
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Diet supplemented with nano zinc oxide
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Diet supplemented with nano and micro zinc oxide
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control non-supplemented diet (24 mg/kg)
Number of subjects: 288
Study: 32847626

Group type: EXPERIMENTAL
Intervention: Prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 80
Study: 33495253

Group type: EXPERIMENTAL
Intervention: Increasing taxes on the product mentioned in the message
Number of subjects: 1850

Group type: EXPERIMENTAL
Intervention: Getting rid of price discounts and special offers on the product mentioned in the message
Number of subjects: 1850

Group type: EXPERIMENTAL
Intervention: Getting rid of low-cost versions of the product mentioned in the message
Number of subjects: 1850

Group type: EXPERIMENTAL
Intervention: Frames regarding children and reducing cancer risk
Number of subjects: 1850

Group type: EXPERIMENTAL
Intervention: Tobacco policies
Number of subjects: 1850

Group type: EXPERIMENTAL
Intervention: Alcohol policies
Number of subjects: 1850

Group type: EXPERIMENTAL
Intervention: Sugary drinks/foods policies
Number of subjects: 1850
Study: 33077817

Group type: EXPERIMENTAL
Intervention: Multimodal intervention (high-intensity interval aerobic fitness and strength training with nutritional supplement)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Exercise training alone (high-intensity interval aerobic fitness and strength training with placebo)
Number of subjects: 148
Study: 35557383

Group type: COMPARATOR
Intervention: Normoxia (Fi O2 = 20.6 ± 0.3%)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hypoxia (Fi O2 = 14.0 ± 0.2%)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both conditions (Normoxia and Hypoxia)
Number of subjects: 21
Study: 34063673

Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation (PNM) treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 37728446

Group type: EXPERIMENTAL
Intervention: PVI-based goal-directed fluid management (GDFM)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional fluid management
Number of subjects: 66
Study: 32966603

Group type: EXPERIMENTAL
Intervention: Video-enhanced care management
Number of subjects: 40

Group type: COMPARATOR
Intervention: Telephone care management
Number of subjects: 40
Study: 32791721

Group type: EXPERIMENTAL
Intervention: Active treatment (3 ml supernatant of maternal vaginal bacteria)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (3 ml sterile water)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active treatment (3 ml supernatant)
Number of subjects: 30
Study: 33802181

Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (ND)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 16
Study: 32463263

Group type: EXPERIMENTAL
Intervention: Aggression polygenic risk scores (PRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internalizing polygenic risk scores (PRS)
Number of subjects: 0
Study: 616858559

Group type: EXPERIMENTAL
Intervention: Indicator-based reminder of catheter removal and standardized Foley care
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no indicator-based reminder)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 33896803

Group type: EXPERIMENTAL
Intervention: Local vibrations (100 Hz)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 10
Study: 32930932

Group type: EXPERIMENTAL
Intervention: 14,552 simple sequence repeat (SSR) markers developed from 21,055 microsatellite repeats using Illumina paired-end sequencing technology.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: SSR markers used to estimate genetic diversity measures.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 15 primers evaluated in S. persica for cross-transferability.
Number of subjects: 3
Study: 34725500

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (Hc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (Mpz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bronchopulmonary dysplasia (BPD) group
Number of subjects: 0
Study: 32918971

Group type: EXPERIMENTAL
Intervention: Single 19 Gy HDR implant to the whole prostate (Trial1)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: MRI-guided focal DIL boost to at least 23 Gy (Trial2)
Number of subjects: 147

Group type: COMPARATOR
Intervention: MRI-guided focal DIL boost
Number of subjects: 147

Group type: COMPARATOR
Intervention: Baseline PSA and Gleason score
Number of subjects: 147
Study: 32184185

Group type: EXPERIMENTAL
Intervention: Minesapride 40 mg
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Minesapride 12 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 32389383

Group type: EXPERIMENTAL
Intervention: Audiovisual resource (video of their own choice)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no audiovisual resource)
Number of subjects: 160
Study: 35301041

Group type: EXPERIMENTAL
Intervention: CBT + Yoga (n = 32)
Number of subjects: 59

Group type: COMPARATOR
Intervention: CBT (n = 27)
Number of subjects: 59
Study: 32445184

Group type: EXPERIMENTAL
Intervention: Etrolizumab
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Etrolizumab 105 mg
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Etrolizumab 210 mg
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: OLEs (Open-Label Extensions)
Number of subjects: 3000
Study: 33523036

Group type: EXPERIMENTAL
Intervention: Autogenic Inhibition Muscle Energy Technique (AI-MET)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Reciprocal Inhibition Muscle Energy Technique (RI-MET)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Static Stretching (SS)
Number of subjects: 78
Study: 32356332

Group type: EXPERIMENTAL
Intervention: RAS with simple chords
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: RAS with complex chords
Number of subjects: 13
Study: 36498963

Group type: EXPERIMENTAL
Intervention: Methylone 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methylone 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methylone 150 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methylone 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: HMMC (compared to methylone)
Number of subjects: 12
Study: 33439036

Group type: EXPERIMENTAL
Intervention: Fusarium venenatum isolates (6 isolates used for inoculation)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Non-inoculated controls
Number of subjects: 600
Study: 34978858

Group type: EXPERIMENTAL
Intervention: Systematic AF screening
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no systematic AF screening)
Number of subjects: 1000
Study: 33514270

Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 3

Group type: COMPARATOR
Intervention: 1 Hz rTMS
Number of subjects: 3
Study: 32338589

Group type: COMPARATOR
Intervention: Control group (no active control arms)
Number of subjects: 35